O⁶-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems

详细信息    查看全文

• 作者：John R. Silber ; Michael S. Bobola ; A. Blank ; Marc C. Chamberlain
• 关键词：BCNU ; 1 ; 3-bis(2-chloroethyl)-1-nitrosourea ; carmustine ; CCNU ; 3-(2-chloroethyl)-3-cyclohexyl-1-nitrosouea ; lomustine ; GBM ; glioblastoma multiforme ; IHC ; immunohistochemistry ; MGMT ; O6-methylguanine-DNA methyltransferase ; MSP ; methylation-specific PCR ; PCV
• 刊名：Biochimica et Biophysica Acta (BBA)/Reviews on Cancer
• 出版年：2012
• 出版时间：August, 2012
• 年：2012
• 卷：1826
• 期：1
• 页码：71-82
• 全文大小：468 K

文摘

Gliomas are the most frequent adult primary brain tumor, and are invariably fatal. The most common diagnosis glioblastoma multiforme (GBM) afflicts 12,500 new patients in the U.S. annually, and has a median survival of approximately one year when treated with the current standard of care. Alkylating agents have long been central in the chemotherapy of GBM and other gliomas. The DNA repair protein O⁶-methylguanine-DNA methyltransferase (MGMT), the principal human activity that removes cytotoxic O⁶-alkylguanine adducts from DNA, promotes resistance to anti-glioma alkylators, including temozolomide and BCNU, in GBM cell lines and xenografts. Moreover, MGMT expression assessed by immunohistochemistry, biochemical activity or promoter CpG methylation status is associated with the response of GBM to alkylator-based therapies, providing evidence that MGMT promotes clinical resistance to alkylating agents. These observations suggest a role for MGMT in directing adjuvant therapy of GBM and other gliomas. Promoter methylation status is the most clinically tractable measure of MGMT, and there is considerable enthusiasm for exploring its utility as a marker to assign therapy to individual patients. Here, we provide an overview of the biochemical, genetic and biological characteristics of MGMT as they relate to glioma therapy. We consider current methods to assess MGMT expression and discuss their utility as predictors of treatment response. Particular emphasis is given to promoter methylation status and the methodological and conceptual impediments that limit its use to direct treatment. We conclude by considering approaches that may improve the utility of MGMT methylation status in planning optimal therapies tailored to individual patients.